10-K: Kraig Biocraft Laboratories Files 10-K, Outlines Progress in Spider Silk Production and Financial Challenges

Kraig Biocraft Laboratories' 10-K filing details advancements in recombinant spider silk production, strategic partnerships, and ongoing financial hurdles.

Summary

• Kraig Biocraft Laboratories, a company focused on developing high-strength fibers using recombinant DNA technology, filed its annual 10-K report.
• The company is using genetically engineered silkworms to produce spider silk proteins for various applications, including textiles and medical implants.
• Kraig's primary technology involves combining spider silk proteins with native silkworm silk proteins to create unique recombinant silk fibers.
• The company has developed two main products: Monster Silk, known for its flexibility, and Dragon Silk, which combines flexibility with high strength.
• In 2023, Kraig focused on strengthening its silkworm strains through selective breeding to improve their robustness for commercial production.
• As of December 2023, one silkworm strain achieved homozygosity for the transgene, with a second strain achieving this in early 2024.
• The company has a strategic partnership with Mthemovement Kings Pte Ltd to develop and sell spider silk fibers under the SpydaSilk brand.
• Kraig has faced financial challenges, with a net loss of $3,029,780 in 2023 and a net capital deficiency, raising concerns about its ability to continue as a going concern.
• The company's cash on hand was $2,551,834 as of December 31, 2023, which is insufficient to meet its planned business objectives without additional financing.
• Kraig is actively pursuing an uplist to a national exchange and is considering acquiring a revenue-producing company to broaden its financial base.

Sentiment

Score: 4

Explanation: The document highlights both positive developments in technology and strategic partnerships, but the significant financial losses and going concern issues weigh heavily on the overall sentiment. The company's future is uncertain without additional funding.

Positives

• The company has made progress in strengthening its silkworm strains for commercial production.
• Kraig has a strategic partnership to commercialize its spider silk fibers.
• The company is exploring opportunities to expand its financial base and market presence.
• Kraig has developed unique recombinant silk fibers with potential applications in various industries.

Negatives

• The company reported a significant net loss of $3,029,780 for 2023.
• Kraig has a net capital deficiency, raising substantial doubt about its ability to continue as a going concern.
• The company's cash resources are insufficient to meet its planned business objectives without additional financing.
• The company has not yet achieved commercial scale production of its spider silk fibers.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• There is a risk that the company may not be able to achieve sustainable revenues and profitable operations.
• The company faces competition from other companies in the spider silk industry.
• The company's research and development efforts may not be successful.
• The company's production operations are subject to risks, including climate acclimation of silkworms and supply chain disruptions.

Future Outlook

The company plans to accelerate and expand commercial scale production of its recombinant spider silk, expand research and development, develop a line of fabrics and apparel, and continue the expansion of its overseas production operations. The company will also consider buying an established revenue producing company in a compatible business, and actively consider pursuing collaborative research opportunities with private laboratories.

Management Comments

• Management believes that its new platform technology will allow it to outpace and surpass Dragon Silk.
• Management anticipates that significant additional expenditures will be necessary to develop and expand our business before significant positive operating cash flows can be achieved.
• Management has undertaken steps as part of a plan to improve operations with the goal of sustaining our operations for the next twelve months and beyond.

Industry Context

The company operates in the emerging spider silk industry, competing with companies like Bolt Threads, Spiber Inc., and AMSilk. The technical textile market, which Kraig is targeting, is estimated to reach $250 billion by 2027. The company believes its technology offers a more cost-effective and environmentally friendly approach compared to its competitors.

Comparison to Industry Standards

• Kraig's approach of using genetically engineered silkworms for spider silk production differs from competitors like Bolt Threads and Spiber, which use fermentation processes.
• The company believes its method is more cost-effective and environmentally friendly than the fermentation processes used by competitors.
• Kraig's focus on combining spider silk proteins with native silkworm proteins is a unique approach in the industry.
• While competitors have raised and spent hundreds of millions of dollars, Kraig is attempting to leverage existing silk production infrastructure to reduce capital expenditure.
• The company's competitors have not yet demonstrated cost-effective results, which Kraig believes it can achieve through its approach.

Related Party Transactions

• Between June 6, 2016, and December 1, 2020 the Company received a total of $1,657,000 in loans from its founder and CEO.
• As of December 31, 2023, the Company owed $6,584,648 to its related parties in accrued salaries and accrued interest.
• As of December 31, 2023, the Company owed $65,292 in royalty agreement payable to its Chief Executive Officer.
• During the year ended December 31, 2022, the Company paid $98,480 as a deposit towards the purchase of inventory from a related party vendor.
• On December 13, 2023, the Company issued a 10-year option to purchase 10,000,000 shares of common stock at an exercise price of $0.04 per share to a related party for services rendered.
• On December 13, 2023, the Company issued a 5-year option to purchase 6,000,000 shares of common stock at an exercise price of $0.04 per share to a related party for services rendered.
• On December 13, 2023, the Company issued a 5-year option to purchase 4,000,000 shares of common stock at an exercise price of $0.04 per share to a related party for services rendered.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential equity financing.
• Employees may be impacted by the company's financial instability.
• Customers may experience delays in product availability due to production challenges.
• Creditors face the risk of non-payment due to the company's financial difficulties.
• Suppliers may be affected by the company's ability to pay for materials and services.

Next Steps

• The company plans to accelerate and expand commercial scale production of its recombinant spider silk.
• The company plans to expand its research and development to accelerate its work in creating next generation materials and to improve the robustness of its recombinant spider silk lines.
• The company plans to develop a line of fabrics and apparel, to create a line of recombinant spider silk fashion wear under.
• The company plans to continue the expansion of its overseas production operations, including working with local contractors or cooperatives and the hiring of additional direct staff, as needed.
• The company plans to overcome the current bottleneck in production by improving the overall robustness of its recombinant spider silk lines through a combination of climate acclimation and implementation of a multiple-strain hybrid breeding program.
• The company plans to accelerate both its microbiology and selective breeding programs, as well as provide more resources for its material testing protocols.
• The company will consider buying an established revenue producing company in a compatible business, in order to broaden its financial base and facilitate the commercialization of its products.
• The company will also actively consider pursuing collaborative research opportunities with private laboratories in areas of research which overlap the company's existing research and development.
• The company plans to actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile and other industries.
• The company plans to actively pursue additional collaborative commercialization, marketing and manufacturing opportunities with companies in the textile and material sectors for the fibers it developed and for any new polymers that it creates in 2024 and going forward.
• The company plans to actively pursue an uplist to a national exchange if such an opportunity presents itself.

Key Dates

Keywords

spider silk, recombinant DNA, silkworms, technical textiles, biotechnology, Dragon Silk, Monster Silk, homozygosity, strategic partnership, financial deficiency, capital raise, OTCQB, Nasdaq